PERSON
Biopharma Layoff Tracker 2024: uniQure, Vir, Arbutus, and More Cut Staff
biopharma layoffs, uniQure, Vir, Arbutus, biotech industry, job cuts, restructuring initiatives
Adaptimmune Receives FDA Accelerated Approval for T Cell Receptor Cell Therapy in Rare Soft Tissue Cancer
Adaptimmune, FDA approval, T cell receptor cell therapy, synovial sarcoma, rare soft tissue cancer, afamitresgene autoleucel, TECELRA
Gene Therapy Pioneer Jim Wilson Departs UPenn to Launch Two New Biotech Companies
Jim Wilson, UPenn, gene therapy, biotech companies, GEMMA Biotherapeutics, Franklin Biolabs
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss
FDA Decision on Vertex’s Non-Opioid Analgesic Suzetrigine Due Early Next Year
FDA, Vertex, Suzetrigine, Non-Opioid Analgesic, Acute Pain, PDUFA, Priority Review
Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency
Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy
FDA Criticizes Brittany Mahomes’ Paid Instagram Post for Kaléo’s Auvi-Q
FDA, Brittany Mahomes, Kaléo, Auvi-Q, misleading advertisement, social media regulation, pharmaceutical marketing
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure
Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback
Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.
Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata
Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology